A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes - PubMed (original) (raw)
. 1986 May 1;136(9):3282-7.
- PMID: 3082984
A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes
P J Martin et al. J Immunol. 1986.
Abstract
We previously described a cell surface antigen, termed Tp44, detected by monoclonal antibody 9.3 on approximately 80% of mature human T lymphocytes. Analysis by SDS-polyacrylamide gel electrophoresis and isoelectric focusing demonstrated that this antigen consists of two identical 44 kilodalton glycopeptides that form a disulfide-linked homodimer. Competitive binding experiments showed that antibody 9.3 and an anti-CD3 antibody (64.1) recognize distinct antigenic determinants; furthermore, the binding of antibody 9.3 was unaffected by prior modulation of CD3. Thus, Tp44 has no detectable cell surface association with CD3. By itself, antibody 9.3 had no detectable effect on either IL 2 receptor expression or IL 2 release, and did not cause T cell proliferation even when monocytes were present and exogenous IL 2 was provided, indicating that binding of antibody 9.3 does not provide a primary signal for T cell activation. However, the proliferative responses of T lymphocytes activated by phytohemagglutinin, concanavalin A, or an anti-CD3 monoclonal antibody were strikingly enhanced in the presence of antibody 9.3, an effect associated with increased IL 2 receptor expression and increased IL 2 secretion. Antibody 9.3 enabled anti-CD3-Sepharose-activated T cells and anti-CD3 antibody-activated Jurkat cells to release IL 2 in the absence of monocytes. Fab fragments of antibody 9.3 had no effect on anti-CD3-induced IL 2 release by Jurkat cells, whereas F(ab')2 fragments had activity comparable to that of unmodified antibody, indicating that bivalent binding of Tp44 molecules is required for IL 2 secretion. Together, these results suggest that TP44 may function as a receptor for accessory signals in the activation of T cells.
Similar articles
- Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells.
Ledbetter JA, Martin PJ, Spooner CE, Wofsy D, Tsu TT, Beatty PG, Gladstone P. Ledbetter JA, et al. J Immunol. 1985 Oct;135(4):2331-6. J Immunol. 1985. PMID: 3928743 - Antibody binding to CD5 (Tp67) and Tp44 T cell surface molecules: effects on cyclic nucleotides, cytoplasmic free calcium, and cAMP-mediated suppression.
Ledbetter JA, Parsons M, Martin PJ, Hansen JA, Rabinovitch PS, June CH. Ledbetter JA, et al. J Immunol. 1986 Nov 15;137(10):3299-305. J Immunol. 1986. PMID: 3021852 - [Signals for T cell growth].
Koyasu S. Koyasu S. Seikagaku. 1986 Dec;58(12):1474-7. Seikagaku. 1986. PMID: 3033098 Review. Japanese. No abstract available. - Biological properties of interleukins.
Bendtzen K. Bendtzen K. Allergy. 1983 May;38(4):219-26. doi: 10.1111/j.1398-9995.1983.tb01614.x. Allergy. 1983. PMID: 6307076 Review. No abstract available.
Cited by
- Artificial antigen-presenting cell system reveals CD28's role in modulating T cell functions during human immunodeficiency virus infection.
Kabakibo TS, Arnold E, Padhan K, Lemieux A, Ortega-Delgado GG, Routy JP, Shoukry N, Dubé M, Kaufmann DE. Kabakibo TS, et al. iScience. 2024 Sep 13;27(10):110947. doi: 10.1016/j.isci.2024.110947. eCollection 2024 Oct 18. iScience. 2024. PMID: 39381752 Free PMC article. - CD28 co-stimulation: novel insights and applications in cancer immunotherapy.
Lotze MT, Olejniczak SH, Skokos D. Lotze MT, et al. Nat Rev Immunol. 2024 Jul 25. doi: 10.1038/s41577-024-01061-1. Online ahead of print. Nat Rev Immunol. 2024. PMID: 39054343 Review. - Anti-PD-L1-Based Bispecific Antibodies Targeting Co-Inhibitory and Co-Stimulatory Molecules for Cancer Immunotherapy.
Geng Q, Jiao P. Geng Q, et al. Molecules. 2024 Jan 17;29(2):454. doi: 10.3390/molecules29020454. Molecules. 2024. PMID: 38257366 Free PMC article. Review. - Fcγ receptors and immunomodulatory antibodies in cancer.
Galvez-Cancino F, Simpson AP, Costoya C, Matos I, Qian D, Peggs KS, Litchfield K, Quezada SA. Galvez-Cancino F, et al. Nat Rev Cancer. 2024 Jan;24(1):51-71. doi: 10.1038/s41568-023-00637-8. Epub 2023 Dec 7. Nat Rev Cancer. 2024. PMID: 38062252 Review. - Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties.
Elsayed A, Pellegrino C, Plüss L, Peissert F, Benz R, Ulrich F, Thorhallsdottir G, Plaza SD, Villa A, Mock J, Puca E, De Luca R, Manz MG, Halin C, Neri D. Elsayed A, et al. MAbs. 2023 Jan-Dec;15(1):2220839. doi: 10.1080/19420862.2023.2220839. MAbs. 2023. PMID: 37288872 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources